Dispelling PCOD Myths & Misconceptions with Ayurveda

Polycystic Ovarian Disease (PCOD), a common hormonal disorder, affects millions of women worldwide. Yet it remains enveloped in myths and misconceptions that cause confusion, stigma, and fear (Norman et al., 2007; Teede et al., 2018). These myths often prevent women from seeking appropriate care or fully understanding their condition. Ayurveda, the ancient Indian science of holistic healing, not only offers a comprehensive approach to managing PCOD but also helps clarify these misconceptions with facts rooted in ancient wisdom and modern understanding.

At EliteAyurveda, we focus on addressing PCOD’s root causes through a holistic lens, providing sustainable solutions for long-term wellness.

PCOS Myths & Misconceptions
PCOS Myths & Misconceptions

Myth 1: PCOD Is Just a Problem with Periods

Reality:
While irregular periods are a hallmark of PCOD, the disorder affects much more than just menstrual cycles. PCOD involves hormonal imbalances that impact metabolism, weight, skin, hair, and emotional well-being (Norman et al., 2007).

Ayurvedic Perspective:
Ayurveda correlates PCOD with imbalances in Kapha dosha, as well as Vata and Pitta disruptions affecting hormonal regulation and inflammation (Frawley, 2000; Lad, 2002). Addressing PCOD requires a holistic approach, balancing all three doshas to restore overall health—not just regularizing periods.

Myth 2: PCOD Means You Cannot Conceive

Reality:
While PCOD may complicate ovulation, it does not guarantee infertility. Many women with PCOD conceive naturally or with minimal intervention. Weight management, lifestyle changes, and targeted therapies significantly improve fertility outcomes (Teede et al., 2018).

Ayurvedic Perspective:
Ayurveda emphasizes strengthening Shukra dhatu (reproductive tissue) and optimizing ovulation by balancing doshas. Personalized herbal medications, dietary adjustments, and detoxification therapies improve ovarian health and support natural conception (Frawley, 2000).

Myth 3: Weight Loss Alone Cures PCOD

Reality:
Although maintaining a healthy weight is crucial, it is not the sole solution. Thin women can also have PCOD. Addressing hormonal imbalances, insulin resistance, and emotional health is equally important.

Ayurvedic Perspective:
Ayurveda treats PCOD as a systemic condition rather than focusing solely on weight. Improving digestion (Agni), eliminating toxins (Ama), and restoring dosha balance underlie Ayurvedic care. Weight management is one part of a holistic strategy that includes dietary and lifestyle modifications (Pole, 2013).

Myth 4: Birth Control Pills Are the Only Solution

Reality:
Birth control pills regulate cycles and alleviate symptoms temporarily but do not address underlying hormonal imbalances. Long-term use may cause side effects like mood changes and metabolic issues.

Ayurvedic Perspective:
Ayurveda offers natural alternatives, using personalized herbal medications to restore hormonal balance without relying on synthetic hormones. Stress reduction techniques, detoxification, and lifestyle changes help regulate cycles naturally and sustainably (Lad, 2002; Pole, 2013).

Myth 5: PCOD Only Affects Reproductive Health

Reality:
PCOD is a systemic condition that impacts metabolic health, increasing the risk of diabetes, heart disease, and mental health challenges like anxiety or depression.

Ayurvedic Perspective:
Ayurveda recognizes PCOD as a condition rooted in systemic imbalances. By improving metabolism, digestion, and mental health through herbal medications, dietary changes, and stress management, Ayurveda helps manage the broader impacts of PCOD on overall well-being (Frawley, 2000).

Ayurvedic Approach to Managing PCOD

Ayurvedic management of PCOD involves detoxification, dietary adjustments, personalized herbal formulations, and lifestyle modifications:

  1. Detoxification (Shodhana): Therapies like Virechana (purgation) and Basti (medicated enema) remove toxins and reset metabolic functions (Sharma et al., 2007).
  2. Personalized Herbal Medications: Tailored herbs balance hormones, regulate cycles, and improve ovarian function.
  3. Dietary Guidance:
    • Kapha-balancing foods: Light, warm meals rich in whole grains and vegetables.
    • Minimizing Sugar & Processed Foods: Prevent insulin resistance and Ama accumulation.
  4. Lifestyle Modifications:
    • Stress Management: Yoga, meditation, and Pranayama to lower cortisol and stabilize hormones.
    • Exercise & Sleep Hygiene: Regular physical activity and consistent rest patterns support overall metabolic health.

Emotional Challenges Faced by Women with PCOD

PCOD’s effects on emotional health are significant:

  • Self-Esteem Issues: Acne, weight gain, and hair loss can cause insecurity and social withdrawal.
  • Frustration: Unpredictable symptoms and slow progress lead to impatience or depression.
  • Anxiety About Fertility: Uncertainty about conceiving causes worry and stress.
  • Social Stigma: Misunderstandings about PCOD may invite unsolicited advice or judgment.

Ayurveda integrates mental health support into its care, emphasizing the connection between mind and body for comprehensive healing (Tiwari, 1999).

Case Study: Managing PCOD with Ayurveda

Patient Profile:

  • Name: Shreya (Name Changed)
  • Age: 28
  • Symptoms: Irregular periods, acne, weight gain, and excessive hair growth.

Ayurvedic Treatment at EliteAyurveda:

  1. Detoxification: Monthly Virechana therapy to remove toxins and balance Kapha.
  2. Herbal Medications: Personalized formulations to regulate cycles and improve skin health.
  3. Dietary Adjustments: Kapha-reducing meals emphasizing whole grains, vegetables, and spices.
  4. Lifestyle Practices: Yoga, meditation, and Pranayama to lower stress and enhance hormonal balance.

Outcome:

  • 3 Months: More regular periods, reduced acne.
  • 6 Months: Improved energy, weight stabilization, and reduced hair growth.

Key Takeaways

  • Ayurveda addresses PCOD’s underlying imbalances rather than providing short-term symptom relief.
  • Detoxification, personalized herbal medications, dietary modifications, and lifestyle changes form the foundation of Ayurvedic treatment.
  • Emotional support and stress management practices ensure comprehensive care, empowering women to reclaim their health and confidence.

Conclusion

Dispelling myths about PCOD is crucial for empowering women with accurate information and effective treatment strategies. Ayurveda’s holistic, personalized approach provides a sustainable solution that addresses the root causes of PCOD, enhancing both physical and emotional well-being.

At EliteAyurveda, we specialize in guiding women through their PCOD journey with patient-centered, compassionate care.

Take the first step toward hormonal harmony today. 📞 Contact us at +91 8884722246 🌐 Visit: www.eliteayurveda.com

Related-

Know More About Ayurveda PCOS Treatment.

GET IN TOUCH

Schedule a Visit

Contact us

References

Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine (Baltimore). 2018 Sep;97(39):e12608. [PMC free article] [PubMed]2.

Zhang C, Ma J, Wang W, Sun Y, Sun K. Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. Hum Reprod. 2018 Nov 01;33(11):2096-2106. [PubMed]3.

Norman RJ, Teede HJ. A new evidence-based guideline for assessment and management of polycystic ovary syndrome. Med J Aust. 2018 Sep 01;209(7):299-300. [PubMed]4.

Goyal A, Ganie MA. Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review. Cureus. 2018 Jul 19;10(7):e3004. [PMC free article] [PubMed]5.

Albu D, Albu A. The relationship between anti-Müllerian hormone serum level and body mass index in a large cohort of infertile patients. Endocrine. 2019 Jan;63(1):157-163. [PubMed]6.

Spinedi E, Cardinali DP. The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy. Int J Endocrinol. 2018;2018:1349868. [PMC free article] [PubMed]7.

Puttabyatappa M, Padmanabhan V. Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome. J Mol Endocrinol. 2018 Oct 16;61(4):R161-R184. [PMC free article] [PubMed]8.

Hallajzadeh J, Khoramdad M, Karamzad N, Almasi-Hashiani A, Janati A, Ayubi E, Pakzad R, Sullman MJM, Safiri S. Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis. J Cardiovasc Thorac Res. 2018;10(2):56-69. [PMC free article] [PubMed]9.

Maya ET, Guure CB, Adanu RMK, Sarfo B, Ntumy M, Bonney EY, Lizneva D, Walker W, Azziz R. Why we need epidemiologic studies of polycystic ovary syndrome in Africa. Int J Gynaecol Obstet. 2018 Nov;143(2):251-254. [PubMed]10.

Carvalho LML, Dos Reis FM, Candido AL, Nunes FFC, Ferreira CN, Gomes KB. Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review. Endocr Regul. 2018 Oct 01;52(4):208-221. [PubMed]11.

Marciniak A, Lejman-Larysz K, Nawrocka-Rutkowska J, Brodowska A, Songin D. [Polycystic ovary syndrome – current state of knowledge]. Pol Merkur Lekarski. 2018 Jun 27;44(264):296-301. [PubMed]12.

Sala Elpidio LN, de Alencar JB, Tsuneto PY, Alves HV, Trento Toretta M, It Taura SK, Laguila Visentainer JE, Sell AM. Killer-cell immunoglobulin-like receptors associated with polycystic ovary syndrome. J Reprod Immunol. 2018 Nov;130:1-6. [PubMed]13.

Shorakae S, Ranasinha S, Abell S, Lambert G, Lambert E, de Courten B, Teede H. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol (Oxf). 2018 Nov;89(5):628-633. [PubMed]14.

Xie J, Burstein F, Garad R, Teede HJ, Boyle JA. Personalized Mobile Tool AskPCOS Delivering Evidence-Based Quality Information about Polycystic Ovary Syndrome. Semin Reprod Med. 2018 Jan;36(1):66-72. [PubMed]15.

Boyle JA, Xu R, Gilbert E, Kuczynska-Burggraf M, Tan B, Teede H, Vincent A, Gibson-Helm M. Ask PCOS: Identifying Need to Inform Evidence-Based App Development for Polycystic Ovary Syndrome. Semin Reprod Med. 2018 Jan;36(1):59-65. [PubMed]16.

Misso ML, Tassone EC, Costello MF, Dokras A, Laven J, Moran LJ, Teede HJ., International PCOS Network. Large-Scale Evidence-Based Guideline Development Engaging the International PCOS Community. Semin Reprod Med. 2018 Jan;36(1):28-34. [PubMed]17.

Tay CT, Moran LJ, Wijeyaratne CN, Redman LM, Norman RJ, Teede HJ, Joham AE. Integrated Model of Care for Polycystic Ovary Syndrome. Semin Reprod Med. 2018 Jan;36(1):86-94. [PubMed]18.

Htet T, Cassar S, Boyle JA, Kuczynska-Burggraf M, Gibson-Helm M, Chiu WL, Stepto NK, Moran LJ. Informing Translation: The Accuracy of Information on Websites for Lifestyle Management of Polycystic Ovary Syndrome. Semin Reprod Med. 2018 Jan;36(1):80-85. [PubMed]19.

Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M. Body composition is improved during 12 months’ treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab. 2014 Jul;99(7):2584-91. [PubMed]20.

Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, Mir FA, Taing S. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab. 2013 Sep;98(9):3599-607. [PubMed]21.

Glintborg D, Andersen M. Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. Curr Opin Obstet Gynecol. 2017 Dec;29(6):390-396. [PubMed]22.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ., International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018 Sep;89(3):251-268. [PMC free article] [PubMed]23.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ., International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379. [PMC free article] [PubMed]24.

Glintborg D, Mumm H, Holst JJ, Andersen M. Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocr Connect. 2017 May;6(4):267-277. [PMC free article] [PubMed]25.

Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet. 2016 Mar;293(3):509-15. [PubMed]26.

Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Aug;39(2):332-342. [PubMed]27.

Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ. Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. J Clin Endocrinol Metab. 2020 Jan 01;105(1):136-51. [PMC free article] [PubMed]28.

Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, Khan AY, Kilpatrick ES, Atkin SL, Sathyapalan T. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clin Endocrinol (Oxf). 2019 Jun;90(6):805-813. [PubMed]29.

Tay CT, Joham AE, Hiam DS, Gadalla MA, Pundir J, Thangaratinam S, Teede HJ, Moran LJ. Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Clin Endocrinol (Oxf). 2018 Nov;89(5):535-553. [PubMed]30.

Zeng L, Yang K. Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018 Jan;59(1):30-38. [PubMed]31.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ., International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 01;33(9):1602-1618. [PMC free article] [PubMed]32.

Armeni E, Lambrinoudaki I. Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome. Curr Vasc Pharmacol. 2019;17(6):579-590. [PubMed]33.

Neven ACH, Laven J, Teede HJ, Boyle JA. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Reprod Med. 2018 Jan;36(1):5-12. [PubMed]

Related Posts:

RELATED ARTICLESMORE FROM AUTHOR